{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:16:51Z","timestamp":1792801011919,"version":"4.5.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19187920"],"award-info":[{"award-number":["19187920"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22579974"],"award-info":[{"award-number":["22579974"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High-grade meningiomas (HGMs) recurring after X-ray treatment show a poor prognosis. We assessed the effectiveness and safety of boron neutron capture therapy (BNCT) in patients with refractory recurrent HGMs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase II investigator-led randomized controlled trial utilized an accelerator-based BNCT system to treat refractory recurrent HGMs. Patients were randomly assigned in a 2:1 ratio to the BNCT (12 patients) and control (6 patients) arms. Progression-free survival (PFS) judged by an independent third-party committee was the primary endpoint and PFS judged by the investigators and overall survival of the BNCT arm were the secondary endpoints. The control arm received rescue BNCT if they show disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three and two patients with World Health Organization (WHO) grade 3 disease were assigned to the BNCT and control arms, respectively; the remaining patients had WHO grade 2 disease. Median PFS (primary endpoint) was 14.4 months (95% CI: 7.9-26.4) in the BNCT arm and 1.4 months (95% CI: 1.0-9.0) in the control arm. Median PFS (secondary endpoint) was 14.7 months (95% CI: 7.6-22.8) in the BNCT arm and 1.5 months (95% CI: 1.0-9.0) in the control arm. The differences were statistically significant (log-rank test, P\u2009=\u20090.0157 and P\u2009=\u20090.0002, respectively). Five patients in the control arm received rescue BNCT. The objective response rate in the BNCT arm was 27.3%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Boron neutron capture therapy is an effective treatment for refractory recurrent HGMs. Compared with conventional therapy, PFS in both primary and secondary endpoints were considerably improved.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noaf279","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:36:14Z","timestamp":1768566974000},"page":"994-1004","source":"Crossref","is-referenced-by-count":5,"title":["Investigator-led clinical trial of boron neutron capture therapy system for recurrent high-grade meningiomas after radiation therapy: Randomized phase II study"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3192-4065","authenticated-orcid":false,"given":"Hideki","family":"Kashiwagi","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Takatsuki City,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1856-7123","authenticated-orcid":false,"given":"Masahiko","family":"Wanibuchi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Takatsuki City,","place":["Japan"]},{"name":"Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University , Takatsuki City,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8968-7125","authenticated-orcid":false,"given":"Naokado","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Takatsuki City,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4140-2415","authenticated-orcid":false,"given":"Naosuke","family":"Nonoguchi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Takatsuki City,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-1410","authenticated-orcid":false,"given":"Motomasa","family":"Furuse","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Takatsuki City,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5007-5279","authenticated-orcid":false,"given":"Shinji","family":"Kawabata","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Takatsuki City,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9603-0567","authenticated-orcid":false,"given":"Keiji","family":"Nihei","sequence":"additional","affiliation":[{"name":"Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University , Takatsuki City,","place":["Japan"]},{"name":"Department of Radiation Oncology, Osaka Medical and Pharmaceutical University , Takatsuki City,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2702-3344","authenticated-orcid":false,"given":"Naonori","family":"Hu","sequence":"additional","affiliation":[{"name":"Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University , Takatsuki City,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Akita","sequence":"additional","affiliation":[{"name":"Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University , Takatsuki City,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ono","sequence":"additional","affiliation":[{"name":"Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University , Takatsuki City,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8056-1016","authenticated-orcid":false,"given":"Shin-Ichi","family":"Miyatake","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Takatsuki City,","place":["Japan"]},{"name":"Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University , Takatsuki City,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"2026043000072111100_noaf279-B1","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s13311-022-01249-0","article-title":"Major features of the 2021 WHO classification of CNS tumors","volume":"19","author":"Smith","year":"2022","journal-title":"Neurotherapeutics"},{"key":"2026043000072111100_noaf279-B2","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026043000072111100_noaf279-B3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/neuonc\/noac137","article-title":"Low-risk meningioma: initial outcomes from NRG Oncology\/RTOG 0539","volume":"25","author":"Rogers","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026043000072111100_noaf279-B4","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026043000072111100_noaf279-B5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11060-020-03674-7","article-title":"Meta-analysis of adjuvant radiotherapy for intracranial atypical and malignant meningiomas","volume":"152","author":"Unterberger","year":"2021","journal-title":"J Neurooncol"},{"key":"2026043000072111100_noaf279-B6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s11060-022-03978-w","article-title":"Multisession radiosurgery for grade 2 (WHO), high risk meningiomas. A phase II clinical trial","volume":"157","author":"Marchetti","year":"2022","journal-title":"J Neurooncol"},{"key":"2026043000072111100_noaf279-B7","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1215\/15228517-2008-107","article-title":"Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas","volume":"11","author":"Miyatake","year":"2009","journal-title":"Neuro Oncol"},{"key":"2026043000072111100_noaf279-B8","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1259\/bjr\/56953620","article-title":"Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential","volume":"83","author":"Sk\u00f6ld","year":"2010","journal-title":"BJR"},{"key":"2026043000072111100_noaf279-B9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3171\/2013.5.JNS122204","article-title":"Boron neutron capture therapy for recurrent high-grade meningiomas","volume":"119","author":"Kawabata","year":"2013","journal-title":"J Neurosurg"},{"key":"2026043000072111100_noaf279-B10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1227\/01.neu.0000279727.90650.24","article-title":"Boron neutron capture therapy for malignant tumors related to meningiomas","volume":"61","author":"Miyatake","year":"2007","journal-title":"Neurosurgery"},{"key":"2026043000072111100_noaf279-B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/3579742","article-title":"The radiation biology of boron neutron capture therapy","volume":"151","author":"Coderre","year":"1999","journal-title":"Radiat Res"},{"key":"2026043000072111100_noaf279-B12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11060-008-9699-x","article-title":"Survival benefit of boron neutron capture therapy for recurrent malignant gliomas","volume":"91","author":"Miyatake","year":"2009","journal-title":"J Neurooncol"},{"key":"2026043000072111100_noaf279-B13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/neuonc\/noab108","article-title":"Reactor-based boron neutron capture therapy for 44 cases of recurrent and refractory high-grade meningiomas with long-term follow-up","volume":"24","author":"Takai","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026043000072111100_noaf279-B14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.radonc.2020.11.001","article-title":"Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan ((10)B) for recurrent or locally advanced head and neck cancer (JHN002): an open-label phase II trial","volume":"155","author":"Hirose","year":"2021","journal-title":"Radiother Oncol"},{"key":"2026043000072111100_noaf279-B15","first-page":"vdab067","article-title":"Accelerator-based BNCT for patients with recurrent glioblastoma: a multicenter phase II study","volume":"3","author":"Kawabata","year":"2021","journal-title":"Neurooncol Adv"},{"key":"2026043000072111100_noaf279-B16","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1212\/WNL.0000000000001988","article-title":"Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma","volume":"85","author":"Chamberlain","year":"2015","journal-title":"Neurology"},{"key":"2026043000072111100_noaf279-B17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma","volume":"17","author":"Kaley","year":"2015","journal-title":"Neuro Oncol"},{"key":"2026043000072111100_noaf279-B18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-014-1358-9","article-title":"A phase II trial of PTK787\/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas","volume":"117","author":"Raizer","year":"2014","journal-title":"J Neurooncol"},{"key":"2026043000072111100_noaf279-B19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/neuonc\/noy137","article-title":"Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group","volume":"21","author":"Huang","year":"2019","journal-title":"Neuro Oncol"},{"key":"2026043000072111100_noaf279-B20","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol"},{"key":"2026043000072111100_noaf279-B21","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","article-title":"MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients","volume":"26","author":"Brandes","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026043000072111100_noaf279-B22","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026043000072111100_noaf279-B23","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.apradiso.2011.03.020","article-title":"Experimental verification of beam characteristics for cyclotron-based epithermal neutron source (C-BENS)","volume":"69","author":"Tanaka","year":"2011","journal-title":"Appl Radiat Isot"},{"key":"2026043000072111100_noaf279-B24","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/neuonc\/noad244","article-title":"Efficacy and toxicity of bimodal radiotherapy in WHO grade 2 meningiomas following subtotal resection with carbon ion boost: prospective phase 2 MARCIE trial","volume":"26","author":"Deng","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026043000072111100_noaf279-B25","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1200\/JCO.2015.61.6490","article-title":"Double-Blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005","volume":"33","author":"Ji","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026043000072111100_noaf279-B26","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/neuonc\/noab243","article-title":"Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)","volume":"24","author":"Preusser","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026043000072111100_noaf279-B27","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1002\/cncr.27460","article-title":"Trabectedin has promising antineoplastic activity in high-grade meningioma","volume":"118","author":"Preusser","year":"2012","journal-title":"Cancer"},{"key":"2026043000072111100_noaf279-B28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020483","article-title":"The role of pharmacotherapy in treatment of meningioma: a systematic review","volume":"15","author":"Shahbandi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026043000072111100_noaf279-B29","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/neuonc\/noaf009","article-title":"Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: a RANO group systematic review and meta-analysis to guide clinical trial design","volume":"27","author":"Kotecha","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026043000072111100_noaf279-B30","doi-asserted-by":"crossref","first-page":"110271","DOI":"10.1016\/j.radonc.2024.110271","article-title":"Re-irradiation for recurrent intracranial meningiomas: analysis of clinical outcomes and prognostic factors","volume":"195","author":"Desideri","year":"2024","journal-title":"Radiother Oncol"},{"key":"2026043000072111100_noaf279-B31","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijrobp.2018.05.011","article-title":"Radiologic response and disease control of recurrent intracranial meningiomas treated with reirradiation","volume":"102","author":"Lin","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026043000072111100_noaf279-B32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11060-019-03342-5","article-title":"Brachytherapy with surgical resection as salvage treatment for recurrent high-grade meningiomas: a matched cohort study","volume":"146","author":"Mooney","year":"2020","journal-title":"J Neurooncol"},{"key":"2026043000072111100_noaf279-B33","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/neuonc\/not330","article-title":"Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review","volume":"16","author":"Kaley","year":"2014","journal-title":"Neuro Oncol"},{"key":"2026043000072111100_noaf279-B34","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/neuonc\/not020","article-title":"Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases","volume":"15","author":"Miyatake","year":"2013","journal-title":"Neuro Oncol"},{"key":"2026043000072111100_noaf279-B35","first-page":"272","article-title":"A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis(\u2020)","volume":"3","author":"Furuse","year":"2016","journal-title":"Neurooncol Pract"},{"key":"2026043000072111100_noaf279-B36","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.ijrobp.2009.12.061","article-title":"Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system","volume":"79","author":"Levin","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026043000072111100_noaf279-B37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13014-024-02486-7","article-title":"Re-irradiation of anaplastic meningioma: higher dose and concomitant bevacizumab may improve progression-free survival","volume":"19","author":"Haisraely","year":"2024","journal-title":"Radiat Oncol"},{"key":"2026043000072111100_noaf279-B38","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ijrobp.2010.06.012","article-title":"Validation and simplification of the radiation therapy oncology group recursive partitioning analysis classification for glioblastoma","volume":"81","author":"Li","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026043000072111100_noaf279-B39","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1093\/neuonc\/noae082","article-title":"Meningioma: international consortium on meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients","volume":"26","author":"Wang","year":"2024","journal-title":"Neuro Oncol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaf279\/66487936\/noaf279.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/4\/994\/66487936\/noaf279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/4\/994\/66487936\/noaf279.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:07:33Z","timestamp":1777522053000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/4\/994\/8432337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,1,21]]},"published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaf279","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,1,21]]}}}